Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
Circulation, 106 (2002), pp. 3143-3421
[2.]
Randomised trial of cholesterol lowering in 4.444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (45).
Lancet, 344 (1994), pp. 1383-1389
[3.]
J. Shepherd, S.M. Cobbe, J. Ford, et al.
for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
N Engl J Med, 333 (1995), pp. 1301-1307
[4.]
F.M. Sacks, M.A. Pfeffer, L.A. Moye, et al.
for The Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
N Engl J Med, 335 (1996), pp. 1001-1009
[5.]
Post Coronary Bypass Graft Trial Investigators. The effect aggressive lowering of low-density lipoprotein cholesterol levels and lowdose anticoagulation on obstructive changes in saphenous-vein coronary-artery-bypass grafts.
Engl J Med, 153 (1997), pp. 153-162
[6.]
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
N Engl H Med, 339 (1998), pp. 1349-1357
[7.]
J.R. Downs, M. Cleardieldl, S. Weis, et al.
for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS.
Jama, 279 (1998), pp. 1615-1622
[8.]
P.W. Serruys, P. De Feyter, C. Macaya, et al.
Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention.
Jama, 287 (2002), pp. 3215-3222
[9.]
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals.
Lancet, 360 (2002), pp. 7-22
[10.]
P. Sever, B. Dahlöf, N.R. Poulter, H. Wedel, G. Beevers, M. Caulfield, et al.
for the ASCOT. Prevention of coronary and stroke events with atorvastatin in hypertesive patients who have average or lower- than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOTLLA): a multicentre randomised controlled trial.
Lancet, 361 (2003), pp. 1149-1158
[11.]
P. Sever, B. Dahlöf, N.R. Poulter, H. Wedel, G. Beevers, M. Caulfield, et al.
for the ASCOT. Justificación, diseño, métodos y características demográficas basales de los participantes en el estudio ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial.
Journal of Hypertension, 19 (2001), pp. 1139-1147
[12.]
Sociedad Española.
de Arteriosclerosis (SEA). Las enfermedades cardiovasculares y sus factores de riesgo en.
[13.]
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin versus Usual Care.
Jama, 288 (2002), pp. 2998-3007
[14.]
Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatina en individuos ancianos con riesgo de enfermedad vascular (PROSPER): un ensayo controlado y aleatorio.
Lancet, 360 (2002), pp. 1623-1630
[15.]
The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high-risk patients.
N Engl J Med, 342 (2000), pp. 145-153
[16.]
B. Dahlof, R.B. Devereux, S.E. Kjeldesen, et al.
Cardiovascular morbility and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE.
Lancet, 359 (2002), pp. 995-1003
Copyright © 2004. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.